Skip to main content

Table 5 Correlations1 between PROs and clinical endpoints at baseline and week 12, and change from baseline to week 12

From: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Measure Baseline Week 12 Change
  PASI PGA PASI PGA PASI PGA
DLQI Total Score 0.31 0.29 0.67 0.65 0.69 0.71
SF-36       
   Physical Functioning -0.32 -0.14 ns -0.28 -0.25** -0.38 -0.14 ns
   Role-Physical -0.22** -0.14 ns -0.41 -0.37 -0.42 -0.31
   Bodily Pain -0.36 -0.19* -0.47 -0.42 -0.60 -0.44
   General Health -0.08 ns 0.05 ns -0.34 -0.33 -0.34 -0.24**
   Vitality -0.15 ns -0.06 ns -0.37 -0.37 -0.38 -0.31
   Social Functioning -0.23** -0.21** -0.46 -0.38 -0.44 -0.43
   Role-Emotional -0.16 ns -0.06 ns -0.37 -0.29 -0.39 -0.36
   Mental Health -0.17* -0.09 ns -0.46 -0.38 -0.43 -0.36
   Physical Summary -0.28 -0.13 ns -0.35 -0.33 -0.45 -0.25**
   Mental Summary -0.12 ns -0.08 ns -0.44 -0.36 -0.40 -0.42
EQ-5D       
   Index Score -0.40 -0.31 -0.60 -0.51 -0.57 -0.44
   VAS-General Health -0.24** -0.09 ns -0.52 -0.43 -0.43 -0.38
PASI 1.00 0.59 1.00 0.83 1.00 0.75
  1. 1All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, ** p < 0.01, ns = non-significant.